Esmya (ulipristal acetate) - Important Safety Information from Gedeon Richter Plc. as approved by the HPRA

Notice type: 3rd Party Publications

Date: 20/02/2018

 

Problem Or Issue:
Important Safety Information communication from Gedeon Richter Plc. on restrictions on the use of ulipristal acetate, Esmya 5 mg tablet, and important new warnings of serious liver injury and recommendations for liver monitoring.

Important Safety Information - Esmya (ulipristal acetate)
 


« Back